-
Innovation Ranking
NewInnovation Ranking – Viatris Inc
Viatris Inc (Viatris) is a healthcare company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceuticals in multiple forms for various disease conditions related to respiratory, cardiovascular, central nervous system (CNS) system and allergy, skin disease, and cancer. It also offers anti- retrovirals, anaphylaxis products, and active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug...
-
Product Insights
NewObsessive-Compulsive Disorder Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Obsessive-Compulsive Disorder Clinical Trial Market Report Overview Obsessive-compulsive disorder clinical trial market research report provides top line data relating to the clinical trials on obsessive-compulsive disorder. The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials. Key...
-
Company Insights
Innovation and Patenting activity of Viatris Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Viatris Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Norelgestromin in Female Contraception
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Norelgestromin in Female Contraception report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Norelgestromin in Female Contraception Drug Details: Norelgestromin is under development as a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MR-107A02 in Post-Operative Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MR-107A02 in Post-Operative Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MR-107A02 in Post-Operative Pain Drug Details: MR-107A-02 is under development for the...
-
Product Insights
NewEpilepsy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Epilepsy - Global Clinical Trials Review, 2024" provides an overview of Epilepsy Clinical trials scenario. This report provides top line data relating to the clinical trials on Epilepsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Thematic Analysis
Pharma M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Pharma Sector
-
Product Insights
Glaucoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Glaucoma Clinical Trial Report Overview A total of 1,696 glaucoma clinical trials were conducted as of January 2024. The glaucoma clinical trial report provides a comprehensive understanding of the glaucoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Phentolamine Mesylate in Presbyopia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Phentolamine Mesylate in Presbyopia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Phentolamine Mesylate in Presbyopia Drug Details: Phentolamine mesylate (Ryzumvi) is an antihypertensive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-088C in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-088C in Metastatic Ovarian Cancer Drug Details: MHB-088C is under...